CytoMed Therapeutics (GDTC) Shares Outstanding (Weighted Average) (2021 - 2025)
CytoMed Therapeutics (GDTC) has disclosed Shares Outstanding (Weighted Average) for 5 consecutive years, with $9.1 million as the latest value for Q4 2025.
- Quarterly Shares Outstanding (Weighted Average) rose 5.2% to $9.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2025, up 5.2% year-over-year, with the annual reading at $19.2 million for FY2025, 10.1% up from the prior year.
- Shares Outstanding (Weighted Average) hit $9.1 million in Q4 2025 for CytoMed Therapeutics, up from $8.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $9.1 million in Q4 2025 to a low of $5.5 million in Q4 2021.
- Historically, Shares Outstanding (Weighted Average) has averaged $7.5 million across 5 years, with a median of $8.5 million in 2023.
- Biggest five-year swings in Shares Outstanding (Weighted Average): skyrocketed 49.73% in 2023 and later rose 1.59% in 2024.
- Year by year, Shares Outstanding (Weighted Average) stood at $5.5 million in 2021, then increased by 3.48% to $5.7 million in 2022, then soared by 49.73% to $8.5 million in 2023, then grew by 1.59% to $8.7 million in 2024, then increased by 5.2% to $9.1 million in 2025.
- Business Quant data shows Shares Outstanding (Weighted Average) for GDTC at $9.1 million in Q4 2025, $8.7 million in Q4 2024, and $8.5 million in Q4 2023.